Synthekine

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
IL-2 receptor subunits CD25 (IL2RA) and CD122 (IL2RB)Protein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
January 2029 (1)
STK-012Phase 1/2Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Est. primary completion 2029-01 · NCT05098132 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.